Endometrial
cancer:

Endometrial cancer overview

Endometrial cancer is the most common gynecologic cancer. The American Cancer Society estimates that about 66,000 new cases of endometrial cancer will be diagnosed in 2021 and that over 12,000 women will die of endometrial cancer.

Patients with endometrial cancer have a high frequency of mutations in a protein known as beta-catenin. These beta-catenin mutations are often driver mutations leading to high expression of DKK1, rapid disease progression, and poor outcomes. DKN-01 has demonstrated single agent activity in endometrial cancer patients, including a patient with a complete response. The activity of DKN-01 in endometrial cancer was strongest in patients whose tumors were expressing high levels of DKK1.

Posters/manuscripts for the endometrial cancer indication

• Safety and Efficacy of a DKK1 Inhibitor (DKN-01) as Monotherapy or in Combination with Paclitaxel in Patients with Wnt Activated Recurrent Gynecologic Malignancies.
• Patients with recurrent epithelial endometrial cancers (EEC) demonstrated greater clinical benefit in biomarker-selected populations when treated with DKN-01 monotherapy.
• Response to anti-DKK1 Therapy in Uterine Carcinosarcoma: A Case Report